Mytesi
Manufacturing · Italy · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Corso Giacomo Matteotti N.1, Milano, Lom...Website
www.mytesi.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Mytesi
Jaguar Health, Inc. specializes in developing and commercializing plant-based prescription medicines, with a focus on addressing urgent global health needs. Their primary product, Mytesi® (crofelemer), provides symptomatic relief for non-infectious diarrhea in adult patients living with HIV/AIDS who are undergoing antiretroviral therapy. The company is dedicated to sustainability and supports local and Indigenous communities through reforestation programs. Their target clients include healthcare professionals and adult patients affected by HIV-related diarrhea.Explore more
Popular SearchesMytesiSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mytesi your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Mytesi is spiking on competitors!
Click to see if Mytesi had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Mytesi
Product Launch: Get notified when Mytesi launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Mytesi, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Mytesi has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Mytesi has new funding data
Earning: See what the market has to say on Mytesi recently announced quarterly report
Recommended Actions
Find VP level buyers at Mytesi
Find 2 more new buyers
Compare Similar Companies to Mytesi
Compare insights from companies similar to Mytesi, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Mytesi
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Mytesi is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Mytesi is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Mytesi.
Mytesi Tech Stack
A closer look at the technologies used by Mytesi
Mytesi News & Media
MYTESI for Chemotherapy-induced Diarrhea Research 2024: Market Size, Regulatory Milestones, Sales Forecast, Patents, and Insights 2019-2032 - Focus on US, Germany, France, Italy, Spain, UK, and Japan - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "MYTESI Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering. "MYTESI Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about MYTESI for Chemotherapy-induced Diarrhea (CID) in the seven major markets. A detailed picture of the MYTESI for CID in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2Jaguar Health, Inc. Reports 2019 Second Quarter Financial Results
Mytesi® Net Sales and Gross Mytesi® Sales Grew 102% and 93%, Respectively, in Q2 2019 Compared to Q2 2018 SAN FRANCISCO, CA / ACCESSWIRE / August 14, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today reported second quarter 2019 results and issued the following highlights. Financial Highlights (In thousands) Q2 2019 Q2 2018 % ChangeJaguar Health Subsidiary Napo Pharmaceuticals Launches Updated Mytesi.com Website
SAN FRANCISCO, CA / ACCESSWIRE / August 7, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that the Company’s wholly-owned, human-health focused subsidiary, Napo Pharmaceuticals, Inc. (“Napo”), has launched a refreshed version of the Mytesi.com website. Mytesi® is Napo’s FDA-approved drug product indicated for the symptomati
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Mytesi
Sign Up For FreeTo access detailed company insights
Jaguar Health, Inc. specializes in developing and commercializing plant-based prescription medicines, with a focus on addressing urgent global health needs. Their primary product, Mytesi® (crofelemer), provides symptomatic relief for non-infectious diarrhea in adult patients living with HIV/AIDS who are undergoing antiretroviral therapy. The compan... Read More
